Researchers found that a higher dose of the weight loss drug Wegovy® (semaglutide 7.2 mg) led to significant weight loss in adults with obesity. In the STEP UP trial, participants taking this higher dose lost an average of 21% of their body weight over 72 weeks, which is about 23 kg for someone who started at 113 kg. Notably, most of the weight loss came from fat, with 84% of the lost weight attributed to reductions in fat mass, while muscle mass was largely preserved.

This is important for anyone looking to age well and maintain a healthy weight. Losing excess body fat can improve overall health, reduce the risk of chronic diseases, and enhance energy levels. The results showed that about 27% of participants on the higher dose were “early responders,” losing 15% or more of their body weight within the first 24 weeks. This early success could indicate who might achieve the most significant weight loss from the treatment, but even those who didn’t respond quickly still experienced meaningful weight loss.

The STEP UP trial included over 1,400 adults with obesity but without type 2 diabetes. It was a large, well-structured study that provides strong evidence for the effectiveness of semaglutide 7.2 mg. However, while the results are promising, it’s essential to note that this is still a clinical trial setting, and further research is needed to understand long-term effects and how these findings translate to the general population.

If you’re considering weight loss options, it’s worth discussing the potential of medications like Wegovy® with your healthcare provider, especially if you’re struggling with obesity and related health issues. Always consider a holistic approach that includes lifestyle changes alongside any medication.

Source: globenewswire.com